Outcome Comparison between Solumedrol and Dexamethasone in Moderate to Severe COVID Disease
DOI:
https://doi.org/10.53350/pjmhs221651264Keywords:
COVID-19, Patients, Inflammation, Markers, Lungs, PneumoniaAbstract
Introduction: Covid 19 is a disease caused by a virus belonging to SARS Co V2 family of viruses. It primarily effects the lungs resulting in inflammation and pneumonia.
Objectives: The main objective of the study is to compare the outcomes and efficacy of solumedrol and dexamethasone in moderate to severe COVID disease.
Material and methods: This cross sectional study was conducted in THQ Hospital Safdarabad during 2020 to 2021. The data was collected from 100 COVID-19 patients diagnosed with moderate to severe condition of the diseases. The data was collected through non-probability consecutive sampling technique.
Results: The data was collected from 100 patients of moderate to severe COVID-19 condition. There were 35 patients in group I and 65 patients’ group II. The mean age for dexamethasone (group II) was 55.41 ± 10.4 years and solumedrol (group I) was 56.86 ± 9.3 years.
Conclusion: It is concluded that both drugs dexamethasone and solumedrol are effective in improving clinical and biochemical parameters of moderate to severe covid 19 disease.
Downloads
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
